Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: psychopraxis. neuropraxis 4/2016

01.09.2016 | Psychiatrie

Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen

verfasst von: Univ.-Prof. Dr. Luise Poustka

Erschienen in: psychopraxis. neuropraxis | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten
share
TEILEN

Zusammenfassung

Autismus-Spektrum-Störungen (ASS) galten lange als Ausschlusskriterium für die Diagnose einer ADHS. Nach DSM-5 besteht nun die Möglichkeit, eine ADHS zusammen mit ASS zu diagnostizieren. Kinder mit der Doppeldiagnose ASS + ADHS zeigen insgesamt mehr Beeinträchtigungen sowohl hinsichtlich ihrer allgemeinen Psychopathologie als auch ihres Funktionsniveaus. Durch die Differenzierung von Patienten mit ASS mit zusätzlicher ADHS-Symptomatik und Patienten ohne ADHS-Symptomatik wird klinisch eine differenzierte Behandlung der individuellen Psychopathologie erleichtert. In folgendem Beitrag werden evidenzbasierte Therapieoptionen, vor allem in pharmakologischer Hinsicht, für von beiden Störungen Betroffene dargestellt.
Literatur
1.
Zurück zum Zitat Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196–1205 CrossRefPubMed Arnold LE, Aman MG, Cook AM et al (2006) Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:1196–1205 CrossRefPubMed
2.
Zurück zum Zitat Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence o disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet 368(9531):210–215 CrossRefPubMed Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, Charman T (2006) Prevalence o disorders of the autism spectrum in a population cohort of children in South Thames: The Special Needs and Autism Project (SNAP). Lancet 368(9531):210–215 CrossRefPubMed
3.
Zurück zum Zitat Bloch M, Qawasmi A (2011) Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50(10):991–1000 CrossRefPubMedPubMedCentral Bloch M, Qawasmi A (2011) Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: Systematic review and meta-analysis. J Am Acad Child Adolesc Psychiatry 50(10):991–1000 CrossRefPubMedPubMedCentral
4.
5.
Zurück zum Zitat Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F (2012) Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 12(4):461–73 Cortese S, Castelnau P, Morcillo C, Roux S, Bonnet-Brilhault F (2012) Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders. Expert Rev Neurother 12(4):461–73
6.
Zurück zum Zitat Di Martino A, Melis G, Cianchetti C, Zuddas A (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 14:207–218 CrossRefPubMed Di Martino A, Melis G, Cianchetti C, Zuddas A (2004) Methylphenidate for pervasive developmental disorders: safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J Child Adolesc Psychopharmacol 14:207–218 CrossRefPubMed
7.
Zurück zum Zitat Fernández de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 54(1):62–70 CrossRefPubMedPubMedCentral Fernández de la Cruz L, Simonoff E, McGough JJ, Halperin JM, Arnold LE, Stringaris A (2015) Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: Results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry 54(1):62–70 CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Friedrich EV, Sivanathan A, Lim T, Suttie N, Louchart S, Pillen S, Pineda JA (2015) An effective neurofeedback intervention to improve social interactions in children with autism spectrum disorder. J Autism Dev Disord 45(12):4084–4100. doi: 10.​1007/​s10803-015-2523-5 CrossRefPubMed Friedrich EV, Sivanathan A, Lim T, Suttie N, Louchart S, Pillen S, Pineda JA (2015) An effective neurofeedback intervention to improve social interactions in children with autism spectrum disorder. J Autism Dev Disord 45(12):4084–4100. doi: 10.​1007/​s10803-015-2523-5 CrossRefPubMed
9.
Zurück zum Zitat Gadow KD, Devincent CJ, Pomeroy J (2006) ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 36:271–283 CrossRefPubMed Gadow KD, Devincent CJ, Pomeroy J (2006) ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord 36:271–283 CrossRefPubMed
10.
11.
Zurück zum Zitat Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255 CrossRefPubMed Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255 CrossRefPubMed
12.
Zurück zum Zitat Harfterkamp M, van de Loo-Neus Minderaa GR et al (2012) A randomized doubleblind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 51:733–741 CrossRefPubMed Harfterkamp M, van de Loo-Neus Minderaa GR et al (2012) A randomized doubleblind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder. J Am Acad Child Adolesc Psychiatry 51:733–741 CrossRefPubMed
13.
Zurück zum Zitat Hartley S, Sikora D (2009) Which DSM-IV-TR criteria best differentiate high-functioning autism spectrum disorder from ADHD and anxiety disorders in older children? Autism 13(5):485–509 PubMedPubMedCentral Hartley S, Sikora D (2009) Which DSM-IV-TR criteria best differentiate high-functioning autism spectrum disorder from ADHD and anxiety disorders in older children? Autism 13(5):485–509 PubMedPubMedCentral
14.
Zurück zum Zitat Holtmann M, Sonuga-Barke E, Cortese S, Brandeis D (2014) Neurofeedback for ADHD. Child Adolesc Psychiatr Clin N Am 23(4):789–806 CrossRefPubMed Holtmann M, Sonuga-Barke E, Cortese S, Brandeis D (2014) Neurofeedback for ADHD. Child Adolesc Psychiatr Clin N Am 23(4):789–806 CrossRefPubMed
15.
Zurück zum Zitat Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S (2011) Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 53(11):986–993 CrossRefPubMed Holtmann M, Steiner S, Hohmann S, Poustka L, Banaschewski T, Bölte S (2011) Neurofeedback in autism spectrum disorders. Dev Med Child Neurol 53(11):986–993 CrossRefPubMed
16.
Zurück zum Zitat Holtmann M, Bolte S, Poustka F (2007) Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology 40:172–177 CrossRefPubMed Holtmann M, Bolte S, Poustka F (2007) Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology 40:172–177 CrossRefPubMed
17.
Zurück zum Zitat Iizuka C, Yamashita Y, Nagamitsu S, Yamashita T, Araki Y, Ohya T et al (2010) Comparison of the strengths and difficulties questionnaire (SDQ) scores between children with high-functioning autism spectrum disorder (HFASD) and attention-deficit/hyperactivity disorder (AD/HD). Brain Dev 32(8):609–612 CrossRefPubMed Iizuka C, Yamashita Y, Nagamitsu S, Yamashita T, Araki Y, Ohya T et al (2010) Comparison of the strengths and difficulties questionnaire (SDQ) scores between children with high-functioning autism spectrum disorder (HFASD) and attention-deficit/hyperactivity disorder (AD/HD). Brain Dev 32(8):609–612 CrossRefPubMed
18.
Zurück zum Zitat James S, Montgomery P, Williams K (2011) Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 9:CD007992 James S, Montgomery P, Williams K (2011) Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 9:CD007992
19.
Zurück zum Zitat Jahromi LB, Kasari CL, McCracken JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395–404 CrossRefPubMed Jahromi LB, Kasari CL, McCracken JT et al (2009) Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J Autism Dev Disord 39:395–404 CrossRefPubMed
20.
Zurück zum Zitat McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah B, McDougle CJ, Nurmi EL (2014) Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 14(3):295–302 CrossRefPubMed McCracken JT, Badashova KK, Posey DJ, Aman MG, Scahill L, Tierney E, Arnold LE, Vitiello B, Whelan F, Chuang SZ, Davies M, Shah B, McDougle CJ, Nurmi EL (2014) Positive effects of methylphenidate on hyperactivity are moderated by monoaminergic gene variants in children with autism spectrum disorders. Pharmacogenomics J 14(3):295–302 CrossRefPubMed
21.
Zurück zum Zitat Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T et al (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6(1):18 CrossRefPubMedPubMedCentral Mankad D, Dupuis A, Smile S, Roberts W, Brian J, Lui T et al (2015) A randomized, placebo controlled trial of omega-3 fatty acids in the treatment of young children with autism. Mol Autism 6(1):18 CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Nijmeijer JS, Arias-Vasquez A, Rommelse NN et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685 PubMedPubMedCentral Nijmeijer JS, Arias-Vasquez A, Rommelse NN et al (2010) Identifying loci for the overlap between attention-deficit/hyperactivity disorder and autism spectrum disorder using a genome-wide QTL linkage approach. J Am Acad Child Adolesc Psychiatry 49:675–685 PubMedPubMedCentral
23.
Zurück zum Zitat Penzner JB, Dudas M, Saito E et al (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563–573 CrossRefPubMedPubMedCentral Penzner JB, Dudas M, Saito E et al (2009) Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563–573 CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948 (Review) CrossRefPubMed Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am J Psychiatry 164(6):942–948 (Review) CrossRefPubMed
25.
Zurück zum Zitat Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599–610 CrossRefPubMed Posey DJ, Wiegand RE, Wilkerson J, Maynard M, Stigler KA, McDougle CJ (2006) Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:599–610 CrossRefPubMed
26.
Zurück zum Zitat Rao PA, Landa RJ (2013) Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism 18:272–280 CrossRefPubMedPubMedCentral Rao PA, Landa RJ (2013) Association between severity of behavioral phenotype and comorbid attention deficit hyperactivity disorder symptoms in children with autism spectrum disorders. Autism 18:272–280 CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Reichow B, Steiner A, Volkmar F (2012) Cochrane Review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child Health 8(2):266–315 CrossRef Reichow B, Steiner A, Volkmar F (2012) Cochrane Review: social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Evid Based Child Health 8(2):266–315 CrossRef
28.
Zurück zum Zitat Ronald A, Simonoff E, Kuntsi J et al (2008) Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry 49:535–542 CrossRefPubMed Ronald A, Simonoff E, Kuntsi J et al (2008) Evidence for overlapping genetic influences on autistic and ADHD behaviours in a community twin sample. J Child Psychol Psychiatry 49:535–542 CrossRefPubMed
29.
Zurück zum Zitat RUPP Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266–1274 CrossRef RUPP Autism Network (2005) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62:1266–1274 CrossRef
30.
Zurück zum Zitat Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 32:575–583 Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P (2006) Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 32:575–583
31.
Zurück zum Zitat Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ, Research Units on Pediatric Psychopharmacology Autism Network (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 172(12):1197–1206. doi: 10.​1176/​appi.​ajp.​2015.​15010055 CrossRefPubMed Scahill L, McCracken JT, King BH, Rockhill C, Shah B, Politte L, Sanders R, Minjarez M, Cowen J, Mullett J, Page C, Ward D, Deng Y, Loo S, Dziura J, McDougle CJ, Research Units on Pediatric Psychopharmacology Autism Network (2015) Extended-release guanfacine for hyperactivity in children with autism spectrum disorder. Am J Psychiatry 172(12):1197–1206. doi: 10.​1176/​appi.​ajp.​2015.​15010055 CrossRefPubMed
32.
Zurück zum Zitat Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921–929 CrossRefPubMed Simonoff E, Pickles A, Charman T et al (2008) Psychiatric disorders in children with autism spectrum disorders: Prevalence, comorbidity, and associated factors in a population-derived sample. J Am Acad Child Adolesc Psychiatry 47:921–929 CrossRefPubMed
33.
Zurück zum Zitat Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 54(5):527–535 CrossRefPubMed Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F (2013) Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability. J Child Psychol Psychiatry 54(5):527–535 CrossRefPubMed
34.
Zurück zum Zitat Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol 16:611–619 CrossRefPubMed Troost PW, Steenhuis MP, Tuynman-Qua HG et al (2006) Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. J Child Adolesc Psychopharmacol 16:611–619 CrossRefPubMed
35.
Zurück zum Zitat Yoshida Y, Uchiyama T (2004) The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 13(5):307–314 CrossRefPubMed Yoshida Y, Uchiyama T (2004) The clinical necessity for assessing Attention Deficit/Hyperactivity Disorder (AD/HD) symptoms in children with high-functioning Pervasive Developmental Disorder (PDD). Eur Child Adolesc Psychiatry 13(5):307–314 CrossRefPubMed
Metadaten
Titel
Zur Therapie von ADHS bei komorbiden Autismus-Spektrum-Störungen
verfasst von
Univ.-Prof. Dr. Luise Poustka
Publikationsdatum
01.09.2016
Verlag
Springer Vienna
Erschienen in
psychopraxis. neuropraxis / Ausgabe 4/2016
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI
https://doi.org/10.1007/s00739-016-0337-7